Fig. 1 | Scientific Reports

Fig. 1

From: Changes in methylation associated with development of metabolic syndrome in testicular cancer patients treated with cisplatin chemotherapy

Fig. 1

Overview of the study design. Left panel: The original discovery study involved Norwegian TC patients that resulted in CpGs list candidates associated with the effects of CBCT and MetS, 16 years after CBCT. Additionally, literature studies were conducted to support the selection of candidates for replication studies. Right panel: In this prospective study on TC survivors from the Netherlands, DNA methylation levels were measured before start of CBCT, 1 month after and 1 year after CBCT. Information on MetS was available prior to treatment and up to 5 years after the treatment. PtAUC was modeled by measurements of platinum levels within the first year after start of CBCT. The figure was created using BioRender.com. CBCT = cisplatin-based chemotherapy; MetS = metabolic syndrome; PtAUC = exposure to platinum measured as area under the curve (AUC); TC = testicular cancer. Definition of persistent MetS status: once a patient is diagnosed with MetS, there is no possibility to escape from this.

Back to article page